Related Experiment Video

Updated: Dec 21, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

10.8K

A Fast and Clean BTK Inhibitor

Ronen Gabizon1, Nir London1

  • 1Department of Organic Chemistry, Weizmann Institute of Science, Rehovot 7600001, Israel.

Journal of Medicinal Chemistry
|May 14, 2020
PubMed

Insights

Remibrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor with high selectivity, offering a potential new treatment for autoimmune diseases. Its unique properties allow for rapid engagement and clearance, minimizing systemic exposure and side effects.

Area of Science:

  • Immunology
  • Pharmacology
  • Oncology

Background:

  • Bruton's tyrosine kinase (BTK) is crucial in B-cell malignancies.
  • Current BTK inhibitors have off-target effects limiting their use in autoimmune diseases.
  • There is a need for selective BTK inhibitors with improved safety profiles.

Purpose of the Study:

  • To introduce Remibrutinib (LOU064), a novel covalent BTK inhibitor.
  • To highlight Remibrutinib's unique selectivity and pharmacokinetic properties.
  • To discuss its potential therapeutic applications in autoimmune and inflammatory conditions.

Main Methods:

  • Development of a novel covalent BTK inhibitor, Remibrutinib.
  • Characterization of Remibrutinib's binding to an inactive BTK conformation.
  • Evaluation of in vivo BTK engagement and plasma clearance.

Main Results:

  • Remibrutinib demonstrates unprecedented selectivity for BTK.
  • Optimization resulted in rapid BTK engagement in vivo.
  • Fast clearance of Remibrutinib limits systemic exposure.

Conclusions:

  • Remibrutinib's high selectivity and favorable pharmacokinetics make it a promising candidate for treating B-cell malignancies.
  • Its safety profile may allow for use in autoimmune and inflammatory diseases.
  • Remibrutinib is currently in Phase 2 trials for chronic urticaria and Sjoegren's syndrome.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.2K

Related Concept Videos

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
702
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
3.2K